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Abstract 
Purpose of review - therapeutic hypothermia reduces death or disability in term and near-term 
infants with moderate-severe hypoxic-ischemic encephalopathy. Nevertheless, many infants 
still survive with disability, despite hypothermia, supporting further research into ways to 
further improve neurologic outcomes. Recent findings - recent clinical and experimental 
studies have refined our understanding of the key parameters for hypothermic neuroprotection, 
including timing of initiation, depth, and duration of hypothermia, and subsequent rewarming 
rate. However, important knowledge gaps remain. There is encouraging clinical evidence from 
a small phase II trial that combined treatment of hypothermia with recombinant erythropoietin 
further reduces risk of disability but definitive studies are still needed. Summary - In 
conclusion, recent studies suggest that current protocols for therapeutic hypothermia are near-
optimal, and that the key to better neurodevelopmental outcomes is earlier diagnosis and 
initiation of hypothermia after birth. Further research is essential to find and evaluate ways to 
further improve outcomes after hypoxic-ischemic encephalopathy, including add-on therapies 
for therapeutic hypothermia and preventing pyrexia during labor and delivery.  
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Introduction 
Hypoxic-ischemic encephalopathy (HIE) around the time of birth represents the single greatest 
contribution to overall disability worldwide and accounts for one-tenth of all disability-
adjusted life years [1]. Even in the developed world, HIE occurs in approximately 2 to 3/1000 
live births at term and near-term [2]. HIE is initiated before labor in only about 10% of cases 
as shown by chronic fetal heart rate changes [3], and studies using magnetic resonance 
imaging (MRI) confirm that the great majority of infants with acute HIE do not have 
established brain atrophy [4], suggesting that most brain injury occurs around the time of birth. 
The major advance in neonatal care of HIE has been the successful translation of therapeutic 
hypothermia in to routine practice [5]. Compelling clinical evidence from multiple randomized 
trials shows that therapeutic hypothermia improves survival without disability to infancy and 
mid-childhood, and, moreover, significantly reduces the most severe disability, cerebral palsy 
[6]. Nevertheless, a substantial proportion of infants still survive with disability despite 
treatment with hypothermia. At the time that the large randomized trials were carried out, 
many aspects of the treatment protocols were based on best estimates. The key aim of this 
review is to examine recent studies that have helped refine our understanding of the critical 
parameters for neuroprotection with therapeutic hypothermia, and to highlight knowledge 
gaps.  
Cerebral damage after hypoxia-ischemia: an ‘evolving’ process 
The seminal observation that enabled the translation of therapeutic hypothermia to clinical 
practice was that brain cell death is not necessarily limited to the period of hypoxia-ischemia 
(HI, the ‘primary’ phase of injury), but that HI can precipitate a cascade of biochemical 
processes that lead to delayed cell death hours or even days afterwards. It is now well 
established in term infants and animals that even after severe HI there is often considerable 
cell survival with recovery of oxidative mitochondrial metabolism in a ‘latent’ phase 
characterized by suppression of neural activity and hypoperfusion [7, 8], followed by 
progressive secondary failure of energetic cellular metabolism [9], with late onset of 
stereotypic seizures, cytotoxic edema (i.e. pathological cell swelling, Figure 1) [7] and 
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extracellular accumulation of excitatory amino acids due to reuptake failure by astroglia and 
excessive depolarization-mediated release [8]. The onset of energetic failure after hypoxia-
ischemia is tightly coupled with the appearance of histologic brain damage in animal studies 
[10], and, in human infants, correlates with neurodevelopmental outcome at 1 and 4 years of 
age [11]. More severe HI is typically associated with greater primary cerebral damage [12], 
earlier onset of secondary deterioration, greater neuronal loss [13, 14], and increased risk of 
mortality and adverse neurological outcomes in newborns with HIE [11]. Experimentally, the 
secondary energetic metabolic failure is associated with irreversible release of cytochrome c, 
the terminal electron acceptor of oxidative cellular respiration, from the mitochondria [15], 
indicating that it is mainly a function of evolving cell death. Hence, it is during this relatively 
short ‘latent’ phase before secondary cellular deterioration that therapeutic interventions are 
most likely to improve outcomes. 
This concept, that acute, global hypoxia-ischemia can trigger evolving brain damage with 
characteristic events appearing at different times after the insult, is central to understanding 
studies of neuroprotection. 
Therapeutic hypothermia – from bench to cotside 
Compelling preclinical evidence for hypothermic neuroprotection after hypoxia-ischemia, 
from multiple paradigms [16], led to trials of induced mild hypothermia for moderate to severe 
neonatal HIE. Systematic meta-analysis of 11 randomized controlled clinical trials (RCTs) of 
selective head cooling and whole-body cooling initiated within 6 h of birth, involving 1505 
term and near-term infants (>=35 weeks gestation) with moderate to severe HIE found 
consistent beneficial effects after hypothermia [17]. In these trials, mild induced hypothermia 
was associated with reduced risk of death or major neurodevelopmental disability by 18 
months of age (relative risk (RR) 0.75 (95% confidence interval (CI) 0.68 to 0.83). 
Importantly, cooling reduced mortality (RR 0.75 (95% CI 0.64 to 0.88), 11 studies, 1468 
infants), and reduced neurodevelopmental disability in survivors (RR 0.77 (95% CI 0.63 to 
0.94), 8 studies, 917 infants). 
Long-term follow-up of these studies is still ongoing; the available evidence suggests a similar 
improvement in outcomes in middle childhood after mild induced hypothermia for HIE [18-
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20]. For example, the Total Body Hypothermia for Neonatal Encephalopathy (TOBY) Trial 
found that more children in the hypothermia group survived without neurologic abnormalities 
than in the control group (45% vs. 28%; RR 1.60, 95% CI: 1.15–2.22) [19], with an IQ score 
of 85 or higher (52% vs. 39%; RR 1.31, P=0.04). Consistent with these findings at 18 months 
of age, there was a reduced risk of cerebral palsy (21% vs. 36%, P=0.03) and moderate or 
severe disability (22% vs. 37%, P=0.03).  
Which is better - head or whole-body cooling? 
The brain can be cooled through whole-body or selective head cooling. In essence, systemic 
cooling provides homogenous hypothermia to the cerebral cortex and deep brain structures, 
whereas selective head cooling cools the cortex more than the central brain regions [21]. 
Given that hypoxic-ischemic brain damage often involves cortex and subcortical structures 
(i.e. basal ganglia and thalamus), either strategy is reasonable in principle. There is limited 
evidence for superiority of one compared to the other. For example, a small cohort study found 
a significant reduction in severe cortical lesions with head cooling, but not with body cooling, 
whereas subcortical lesions were equally reduced in both cooling groups in neonates with 
milder aEEG abnormalities [22]. By contrast, another small cohort of infants suggested a 
higher incidence of severe mixed lesions after head cooling compared to whole body cooling 
[23]  
In practice, comprehensive meta-analysis of 7 cooling trials showed highly similar reductions 
in neonatal mortality or major disability with head and whole-body hypothermia in infants 
with HIE [24], and so these strategies appear equivalent. However, it is easier to implement 
systemic cooling with servo-controlled temperature regulation, and thus whole body cooling is 
now used more widely. 
Is it possible to optimize current protocols for therapeutic hypothermia? 
Current protocols for therapeutic hypothermia are incompletely neuroprotective, with a 
number needed to treat of 7 to 9 ((95% CI 5 to 10), 8 studies, 1344 infants) [17]. As reviewed, 
the experimental efficacy of hypothermia is highly dependent on timing of initiation, and depth 
and duration of cooling [25]; critical parameters that were in part based on pilot studies and 
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empiric decisions. This suggested the possibility that it is possible to further optimize the 
clinical regimens for therapeutic hypothermia.  
At the same time, it is important to appreciate that there is some evidence that outcomes may 
have improved now that therapeutic hypothermia is routine care for moderate to severe HIE. In 
a recent randomized controlled trial of cooling strategies, the rate of death or disability at 18 
months of age in infants treated with cooling to 33.5°C for 72 h was 29.3% [26], compared 
with 44% in infants receiving the same cooling protocol in a previous trial that used the same 
recruitment criteria [27]. Consistent with this, recent non-randomized cohort studies of infants 
cooled for HIE suggest both reduced severity of cerebral palsy [28] and lower incidence of 
epilepsy at 2 years of age compared with the original cooling trials [29]. The factors behind 
these apparent improvements in outcome after therapeutic hypothermia are not known. 
Speculatively, they might be related to recruiting infants with less severe HIE as shown by less 
severe Apgar scores in the recent trial [30]. Alternatively, it is plausible that cooling is being 
initiated earlier, with greater use of very early passive cooling while infants with moderate-
severe HIE are assessed for active cooling [31].  
The timing of starting hypothermia - more neuroprotection with less delay 
Delaying initiation of cooling dramatically reduces its efficacy in animal studies [14]. Studies 
in infant and adult rodents and in near-term fetal sheep showed that neuroprotection for 
cooling started within 6 hours after HI could be achieved by extending the duration of 
hypothermia to 48 to 72 hours, until secondary phase events such as high amplitude seizures 
and cytotoxic edema resolved [25]. This concept is highly consistent with the delayed onset of 
mitochondrial failure observed during the latent phase on MRI after moderate to severe HIE in 
human infants [9, 11] and piglets [32] and on near infrared spectroscopy in fetal sheep. The 
effect of delayed initiation was difficult to analyse in the RCTs of therapeutic hypothermia 
because the great majority of infants were randomized late in the latent phase. However, in 
support, a subsequent cohort study of 65 surviving cooled newborns showed that 43 infants in 
whom cooling was started before 3 hours of age had significantly better Psychomotor 
Development Index (PDI) scores (median PDI: 90) than those who were cooled after 3 hours 
(median PDI: 78) [30]. 
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How deep is optimal for hypothermic neuroprotection? 
Similarly, the critical depth of hypothermia required for protection may be affected by multiple 
factors including the delay before initiation and the severity and nature of the insult. There is 
some evidence from studies in adult rodents and in fetal sheep that when cooling was delayed 
until 6 hours after cerebral ischemia greater functional and histological neuroprotection was 
achieved with a 5°C reduction than with 3°C [33, 7]. However, in 7-day old rat pups, cooling 
to 32, 30, 26, or 18°C for 5 h after hypoxia-ischemia, was not associated with additional 
neuroprotection compared to 33.5°C [34]. Similarly, in neonatal piglets, whole-body 
hypothermia after cerebral ischemia with a reduction in body temperature of either 3.5 or 5°C 
was associated with significant and highly similar neuroprotection, whereas a reduction of 8°C 
was detrimental [35]. Finally, a large randomized controlled clinical trial has confirmed that 
cooling infants with moderate to severe HIE to 32°C instead of 33.5°C did not further reduce 
death or moderate to severe disability at 18 months of age [26]. These consistent clinical and 
pre-clinical findings suggest that there is a relatively broad range of cooling temperatures 
beneficial for the brain after hypoxia-ischemia, and that, reassuringly, it should not be 
necessary to reduce core temperatures by more than ~3.5°C. 
If some cooling is good, would more be even better?  
The original RCT protocols required that hypothermia should be continued for 72 hours, based 
on evidence from animal studies that cooling needed to be continued for between 48 and 72 
hours [36, 7]. However, it is not clear whether shorter or more prolonged durations of cooling 
might be either sufficient or potentially more effective, respectively. Robust recent preclinical 
studies now suggest that continuing hypothermia for 72 hours is needed for optimal 
neuroprotection [37, 38]. For example, in near-term fetal sheep, delayed cerebral cooling, 
started 3 h after cerebral ischemia and continued until 48 hours, provided partial protection but 
was substantially less effective for recovery of EEG power and neural survival than cooling for 
72 hours (Figure 1) [38]. Conversely, in the term-equivalent fetal sheep, when delayed 
hypothermia started 3 hours after ischemia was prolonged from 3 to 5 days, there was no 
further improvement in electrophysiological recovery or neuronal survival or reduction in 
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cortical microglial induction [37]. Indeed, extended cooling was associated with a small 
reduction in neuronal survival in the parasagittal cortex and dentate gyrus.  
These preclinical findings have been confirmed by a large clinical trial in 364 infants with 
moderate to severe HIE of prolonged duration and increased depth of therapeutic hypothermia. 
This study was stopped at 50% of planned recruitment due to lack of effect and safety 
concerns [39, 26]. The adjusted risk ratio for death in the neonatal intensive care unit after 
cooling for 120 hours compared to 72 hours was 1.37 (95% CI: 0.92–2.04) and for the 32°C 
compared to 33.5°C was 1.24 (CI: 0.69–2.25). There was no significant overall effect of 
longer or deeper cooling on death or disability at a mean age of 18 months [26]. 
Is speed of rewarming after therapeutic hypothermia important? 
The optimal rate of rewarming after therapeutic hypothermia for HIE is unknown, albeit it is 
widely suggested that slow rewarming is beneficial. The randomized clinical trials of 
therapeutic hypothermia for HIE recommended rewarming neonates at no more than 0.5°C per 
hour [40]. This was largely based on case reports that fast rewarming might destabilize 
cardiovascular function [41], or trigger rebound seizures [42]. However, there is no controlled 
human evidence for the optimal rate of rewarming. 
There is limited evidence from animal studies that rapid rewarming may reverse the 
depression of potential injurious processes such as oxidative stress or excitotoxin release [43, 
44], and slow rewarming may improve neural outcomes. In neonatal piglets exposed to severe 
HI, hypothermia for 18 hours followed by rewarming at 0.5°C/h was associated with less 
caspase-3 activation in the cerebral cortex and white matter tracts than with rewarming at 
4°C/h [45, 46]. Moreover, in adult gerbils subjected to transient forebrain ischemia, fast 
rewarming after hypothermia for 2 hours was associated with transient uncoupling of cerebral 
blood flow and metabolism and loss of neuroprotection in the CA1 region of the hippocampus, 
which was prevented by slow or stepwise rewarming [47]. However, these studies tested very 
short intervals of cooling that are likely to have been highly sub-optimal. 
In near-term fetal sheep, cerebral hypothermia started 3 hours after global cerebral ischemia 
and continued for 48 hours, was associated with a striking deterioration in EEG power and 
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significantly less neuroprotection than 72 hours of hypothermia [38]. In that study, fetuses 
were allowed to rewarm spontaneously, typically reaching control temperatures in 
approximately one hour [48]. After 48 hours of cerebral hypothermia very slow rewarming 
over 24 hours (~0.2°C/h) was associated with improved electrographic recovery compared 
with rapid rewarming (~5°C/h). However, neuronal survival in the cortex and CA4 was still 
significantly less than after 72 hours of hypothermia with fast rewarming (p<0.05) [49]. 
Further studies are needed to test typical clinical rewarming regimes after 72 hours of 
hypothermia, but these data strongly suggest that the overall duration of cooling was more 
important than speed of rewarming after therapeutic hypothermia. 
Is there benefit from cooling initiated later than 6 hours after birth? 
The preclinical and clinical studies reviewed above consistently suggest that hypothermia 
should be started as early as possible in the first 6 hours of life to achieve optimal outcomes. 
However, some infants are unable to be started within this time window, because of late 
diagnosis or being outborn in areas that cannot provide support for cooling. Even though it is 
not optimal, should these infants be offered therapeutic hypothermia after 6 hours of life? A 
recent randomized controlled trial conducted by 21 Neonatal Research Network centers in the 
USA recruited 168 term infants with HIE, in whom therapeutic hypothermia could not be 
started within 6 hours of life. Infants were randomized between > 6 and <24 hours after birth 
to either hypothermia (33 to 34°C) or normothermia (36.5 °C to 37.3°C). The median time to 
start cooling in this trial was 16 hours after birth. Neurodevelopmental outcome was assessed 
in survivors at 18-22 months with the Bayley III. Outcome was available for 78 cooled (9 died 
and 10 had moderate to severe disability) and 79 normothermic patients (9 died and 13 had 
moderate to severe disability) [50]. This difference was not significant (p >0.5, Chi-squared 
test). A Bayesian analysis suggested a 71, 64 or 56% probability of reducing death or disability 
by at least 1, 2 or 3%, respectively. Taken as a whole, this study strongly reinforces the need 
for strong clinical protocols to ensure that therapeutic hypothermia is started in the first 6 
hours after resuscitation for the best chance of a favorable outcome.  
Can we improve care during labor and resuscitation? 
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Collectively, these studies infer that the most likely improvement in outcomes from 
therapeutic hypothermia would result from starting treatment as early as possible within the 
first 6 hours after birth. This strongly suggests that a key aspect of neonatal management must 
be to avoid pyrexia during labor and resuscitation.  
Fetal temperatures are higher than maternal temperatures, as the mother acts as a heat sink for 
the fetus. Thus, maternal pyrexia increases fetal temperature and risk of neural injury during 
HI. In pregnant baboons raising the maternal temperature to between 41 and 42 ºC increased 
uterine activity and the temperature gradient between fetus and mother from 0.47 ºC to 0.75 
[51], and was associated with severe fetal acidosis and hypoxia, hypotension and tachycardia. 
Although there are no randomized controlled trials of temperature control in labor, fever 
during labor has been independently associated in multiple studies with neonatal morbidity, 
including death, neonatal seizures, encephalopathy and neonatal stroke [52-55]. 
Thus, studies of controlling pyrexia in labor are highly desirable and should be developed 
urgently. Pragmatically, it is now widely considered that overhead heaters should be turned off 
during resuscitation of term or near-term infants. During subsequent observation, if 
encephalopathy is suspected, the infants should be managed first with mild passive 
hypothermia followed with active cooling, with strict temperature monitoring. In addition to 
controlling for pyrexia, therapeutic hypothermia is started much sooner after birth using this 
approach. For example, neonates cooled passively during transport reached their target 
temperature (33.5ºC) approximately 2 h faster than infants that were not cooled until arrival at 
the referral center [56]. In a small cohort of 50 infants that received hypothermia, time from 
birth to achieve core temperature <34 °C was 2.6 ± 1.8 h for inborn infants, 3.9 ± 1.6 h for 
infants cooled before and during transport, and 9.8 ± 6.2 h for outborn infants who were not 
cooled until arrival at the hypothermia center [57]. Whether this translates into improved 
hypothermic neuroprotection is still unknown. 
Other populations: Should we cool infants with mild HIE? 
The large RCTs of therapeutic hypothermia excluded infants who had mild HIE in the first 6 
hours of life as it was unknown whether they were at risk of adverse outcomes, and so the 
potential benefit of treating these infants with therapeutic hypothermia is unknown. There is 
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now evidence from cohort studies that some infants with mild HIE, as defined using the trial 
criteria, in the first 6 hours of life have a significant risk of disability [58]. The evidence is 
rather variable, likely because of variable criteria for mild HIE, retrospective identification, 
less formal neurological examinations than used in the prospective trials, or not using aEEG 
criteria. In practice, some of these infants would very likely have been classified as having 
evolved to Stage II (moderate) encephalopathy by Sarnat and Sarnat by 24 h [59], because the 
historical criteria required longitudinal assessment of neurological progress until hospital 
discharge or death plus multimodal assessment, typically including a formal EEG and 
imaging, whereas, in the modern setting, severity is assessed by clinical criteria only within the 
first 6 hours of life. Thus, given the evolving nature of HIE, it is not really possible to 
accurately define mild HIE in the first 6 hours of life. 
One meta-analysis that included studies with well-defined HIE grading at birth, and 
standardized neurodevelopmental assessment at 18 months or older, suggested that 86/341 
(25%) of infants with mild HIE in the first 6 hours of life had an adverse outcome [60], 
defined as death, cerebral palsy or neurodevelopmental test scores that were more than 1 
standard deviation below the mean. A very recent prospective cohort study of mild HIE 
defined as ≥1 neurological abnormality using modified Sarnat criteria within 6 h of birth and 
not meeting cooling criteria, found that 16% of infants had disability at a mean of 19 months 
[61]. Indeed, 40% of infants had Bayley scores more than one standard deviation below the 
mean (< 85) for either cognition, motor, or language. Similarly, a prospective cohort study of 
infants who were not treated with therapeutic hypothermia, suggested that infants with mild 
HIE, determined by both early EEG and clinical examination, had adverse cognitive and 
neuromotor outcomes at 5 years of age [62]. Interestingly, although intact survival was much 
greater after mild than moderate or severe HIE, survivors showed no significant difference in 
cognitive outcomes between those who had had mild compared to moderate HIE. 
Given that this population of infants with mild HIE in the first 6 hours is heterogeneous, the 
balance of clinical risk and benefit is unclear. Treating all such cases would increase the 
numbers of infants being separated from their parents, receiving invasive treatments such as 
central lines, invasive respiratory support, sedation and delayed oral feeding. There is no 
established prognostic method by which clinicians can determine if it is possible to stop 
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cooling before 72 hours [63], and so hypothermia should be continued for 3 days. Supporting 
this concept, in one case series of 10 infants with mild HIE in whom hypothermia was stopped 
early because of rapid clinical improvement, neural injury on magnetic resonance imaging was 
seen in half and disability at 2 years of age in 2 infants [64]. Given that there are roughly as 
many infants with mild HIE as there are with moderate to severe HIE, it is critical that the 
benefits of treatment for this group should be formally tested.  
Summary 
In summary, current evidence suggests that current protocols of whole body or head cooling 
for 72 hours are reasonably close to optimal. Thus, the most effective way to further improve 
outcomes from therapeutic hypothermia in infants with HIE is to initiate cooling earlier, as 
soon as possible in the first 6 hours after birth. Alternatively, hypothermia combined with 
other pharmacological or non-pharmacological interventions may enable further improvements 
in outcome. There is currently considerable interest in such options, based on the endogenous 
induction of potentially protective compounds in the brain as well as exogenous agents [65]. 
What is the potential for add-on therapies? 
There is strong evidence that both programmed cell death and sterile post-ischemic 
inflammation augment cell death pathways in the latent phase, and some evidence that oxygen 
free radicals and excitotoxins may also play a role [65]. Thus, it is reasonable to consider 
whether agents modulating these pathways might augment therapeutic hypothermia. There are 
many trials in progress, as listed in Table 1. The results of recent clinical trials have been 
mixed. For example, in a phase-II trial in newborns with HIE treated with hypothermia, 
treatment with an anticonvulsant, topiramate (n=21), was safe, but did not improve death or 
neurological disability compared with cooling alone (n=23) [66]. The noble gas Xenon has 
significant anti-apoptotic effects via the N-methyl-D-aspartate (NMDA) receptor in piglets 
[67], but did not augment hypothermic neuroprotection in a small phase-II trial (n=46 for both 
groups) as assessed by magnetic resonance spectroscopy measures, including lactate to N-
acetyl aspartate ratio in the thalamus (mean ratio: 1.09; 95% CI: 0.90-1.32) and fractional 
anisotropy (mean difference: -0.01; 95% CI: 0.03-0.02) in the posterior limb of the internal 
capsule [68]. However, this study was limited by delay in starting Xenon until ~10 h after 
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birth, which is outside its reported therapeutic window. A second RCT is still in progress 
(Table 1). More encouragingly, a small trial of 30 infants with HIE randomized to receive 
either the endogenous hormone melatonin plus hypothermia or hypothermia alone, reported 
improved survival at 6 months of age without neurologic or developmental abnormalities [69]. 
However, these findings are preliminary and must be validated in larger trials.  
One of the more promising neurotherapeutics, recombinant erythropoietin (rEpo), has anti-
apoptotic, anti-oxidant, anti-excitotoxic and anti-inflammation effects in preclinical paradigms 
of neonatal brain damage [25]. In addition, it promotes proliferation as well as maturation and 
differentiation of oligodendrocytes and neurons, which at least in principle could help promote 
neurorepair after HI. Small randomized trials in term infants with HIE have reported improved 
outcomes on modern imaging and neurologic measures after monotherapy with rEpo [70-72]. 
Further, a phase-II double-blinded, placebo-controlled randomized trial in infants with 
moderate to severe HIE who received hypothermia plus multiple rEpo doses (1000 U/kg, i.v. 
at 1, 2, 3, 5, and 7 days post-birth), compared to cooling plus placebo, showed reduced 
subcortical and cerebellar brain damage scores on MRI at a mean of 5.1 days, with better 
motor and developmental scores at 12.7 months of age [73]. Two large phase III trials of 
hypothermia plus rEpo are currently recruiting (Table 1). 
CONCLUSION 
Therapeutic hypothermia is now established as standard care to improve neurological recovery 
in infants with moderate to severe hypoxic-ischemic encephalopathy. However, current 
protocols are only partially effective [17]. Further improvement in neurodevelopmental 
outcomes is likely to come from strategies to avoid pyrexia during and after resuscitation, to 
start hypothermia earlier, and co-treatment with endogenous or exogenous neuroprotective 
agents. Early EEG recordings and other biomarkers can help to identify patients who would 
benefit from treatment in such a limited time frame [74]. Endogenous neuroprotective 
compounds such as rEpo are showing particular promise, with multiple potential benefits and 
excellent safety records in other settings.  
The key priorities for further research include: 
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1. Large pragmatic trials to test therapeutic hypothermia in new populations, in particular, 
evaluating the risks and benefits of therapeutic hypothermia for infants with mild HIE. 
2. Studies of improved care in labor, particularly trials to test whether preventing 
maternal pyrexia can reduce the risk of neonatal hypoxic-ischemic encephalopathy. 
3. Preclinical studies to identify and develop more effective neuroprotective interventions 
both in combination with therapeutic hypothermia and for use in settings where 
hypothermia is inappropriate, such as in extremely preterm infants. 
4. Identifying and refining biomarkers such as EEG recordings to robustly identify infants 
with encephalopathy who would benefit from treatment as soon as possible after birth. 
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Table 1. Active trials of neurotherapeutics and therapeutic hypothermia in term neonates with 
hypoxic-ischemic encephalopathy. 
Registratio
n 
Clinical Trial 
Ph
ase 
Treatment Regimen Outcome Measures 
Principal 
Investigator 
01. 
NCT02621
944 
Melatonin as a 
Neuroprotective Therapy in 
Neonates with HIE 
Undergoing Hypothermia 
I 
0.5-5.0 mg/kg Melatonin, 
enteral doses starting 
<12 h of birth, combined 
with therapeutic 
hypothermia* 
MRI at 7-12 days of 
age, BSID-III Index 
Score at 18-20 
months, and GMFA at 
3 and 23 months of 
age 
University of 
Florida, USA 
(Michael D 
Weiss, MD) 
02. 
NCT02812
433 
Sildenafil Administration to 
Treat Neonatal 
Encephalopathy (SANE Trial) 
I 
2 mg/kg/dose Sildenafil 
per os, twice daily on day 
2-9 after birth, combined 
with therapeutic 
hypothermia 
Adverse events at day 
1-14, MRI at 2 and 30 
days, BSID-III Index 
Scores at 1 and 2 
years of age 
McGill 
University, 
Canada (Pia 
Wintermark, 
MD) 
03. 
NCT02700
854 
Hypoxic-Ischemic 
Encephalopathy Therapy 
Optimization in Neonates for 
Improved Protection With 
CO2 (HENRIC Trial) 
I 
5% CO2 through patient 
circuits in ventilators, 
started <6 hours of birth 
for 12 h max, with 
therapeutic cooling 
Death, number 
seizures <1 week, 
Lac/NAA ratio on 
MRS, fractional 
anisotropy on MRI, 
hypotension 
Semmelweis 
University, 
Hungary (Miklos 
Szabo) 
04. 
NCT01765
218 
Topiramate in Neonates 
Receiving Whole Body Cooling 
for Hypoxic-Ischemic 
Encephalopathy 
I/II 
5.0 mg/kg Topiramate, 
enteral doses, given daily 
for 5 days from 
admission, combined 
with therapeutic cooling  
Seizures <4 weeks or 
discharge, MRI at day 
5-7, BSID-III Scores at 
9, 18 and 27 months 
of age 
University of 
California, USA 
(Kristin Hoffman, 
MD) 
05. 
NCT02551
003 
Protective Effect of 
Autologous Cord Blood 
combined with Therapeutic 
Hypothermia Following 
Neonatal Encephalopathy 
I/II 
Autologous Cord Blood, 
i.v. <24 hours, and at 48 
and 72 h of life, 
combined with 
therapeutic hypothermia 
MRI at 7 and 28 days 
and 12 months, death 
or disability; BSID-III 
Score at 18 months 
of age 
Fudan University  
(Wenhao Zhou, 
MD) 
06. 
NCT02881
970 
Neonatal HIE : Safety and 
Feasibility Study of a Curative 
Treatment With Autologous 
Cord Blood Stem Cells 
I/II 
Autologous cord blood 
stem cells; unknown 
regimen, combined with 
therapeutic hypothermia 
Adverse clinical or 
paraclinical events, 
and 
neurodevelopmental 
Hopitaux de 
Marseille 
(Catherine 
Geindre, PhD) 
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(NEOSTEM Trial) outcomes at 22-24 
months 
07. 
NCT02071
394 
Xenon and Cooling Therapy in 
Babies at High Risk of Brain 
Injury Following Poor 
Condition after Birth 
(CoolXenon3 Trial) 
II 
50% Xenon through 
patient circuits in 
ventilators, started <5 h 
of birth for 18 hours, 
with therapeutic 
hypothermia 
MRI <2 weeks of life, 
death or moderate to 
severe impairment; 
BSID-III Score at 18-
24 months  
University of 
Bristol, UK 
(Marianne 
Thoresen, PhD) 
08. 
NCT02434
965 
Autologous Cord Blood and 
Human Placental-Derived 
Stem Cells in Neonates With 
Hypoxic-Ischemic 
Encephalopathy (HPDSC+HIE 
Trial) 
II 
Autologous Cord Blood 
and HPDSC, i.v. unknown 
dose <24 hours and on 
days 2, 3, 7 and 8 
following birth 
Adverse clinical 
events <30 days, 
neurologic condition; 
MRI, DTI and Sarnat 
exam <24 months 
New York 
Medical College, 
USA (Mitchell 
Cairo, MD) 
09. 
NCT02612
155 
A Multi-Site Study of 
Autologous Cord Blood Cells 
for Hypoxic-Ischemic 
Encephalopathy 
II 
Autologous Cord Blood, 
i.v. 2 infusions, started 
<48 hours of life, 
combined with 
therapeutic hypothermia 
Seizures, death or 
moderate to severe 
impairment; BSID-III 
Index Scores at 12 
month of age 
Duke University, 
USA (Michael 
Cotten, MD) 
10. 
NCT03071
861 
Mild Encephalopathy in the 
Newborn Treated With 
Darbepoetin-Alpha (MEND 
Trial) 
II 
10 mcg/kg Darbepoetin 
Alpha i.v. single dose, 
given <24 h after birth 
Adverse events or 
seizures <30 days, 
neurologic outcome; 
GMFA and BSID-III at 
12-18 months 
University of 
New Mexico, 
USA (John 
Philips, MD) 
11. 
NCT03409
770 
Optimising the Duration of 
Cooling in Mild 
Encephalopathy (COMET Trial) 
II/II
I 
Whole-body 
hypothermia (33-34°) 
started <6 h for 24, 48 or 
72 hours, with 
rewarming at 0.5°C per 
hour 
MRI and thalamic N-
acetyl aspartate ratio 
on MRS, obtained at 
4 to 14 days following 
birth 
Imperial College 
London, UK 
(Pete Lally, PhD) 
12. 
NCT03162
653 
Effect of Allopurinol for 
Hypoxic-Ischemic Brain Injury 
on Cognitive Outcome 
(ALBINO Trial) 
III 
20 mg/kg Allopurinol, 
first i.v. dose <30 min of 
birth, 10 mg/kg second 
dose at 12 hours, 
combined with 
hypothermia 
Death or 
neurodevelopmental 
impairment; GMFA 
and BSID-III Index 
Scores at 24 months 
of age 
University 
Hospital 
Tuebingen, 
Germany 
(Rudiger Mario, 
PhD) 
13. High-dose Erythropoietin for III 1000 IU/kg rEpo i.v. <24 Death or moderate to University of 
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NTC02811
263 
Asphyxia and Encephalopathy 
(HEAL Trial) 
h, and at 2, 3, 4, and 7 
days after birth, 
combined with 
therapeutic hypothermia 
severe impairment; 
GMFA and BSID-III 
Scores at 22-26 
months of age 
California, USA 
(Yvonne Wu, 
MD) 
14. 
NCT03163
589 
Erythropoietin in 
Management of Neonatal 
Hypoxic-Ischemic 
Encephalopathy 
III 
1000 IU/kg rEpo i.v. <24 
h, and at 2, 3, 5, 7 and 9 
days after birth, 
combined with 
therapeutic hypothermia 
MRI <2-3 weeks of 
life, death or 
moderate-severe 
impairment; Griffith 
Score at 12 months 
of age 
Assiut 
University, Egypt 
(Samia 
Mohamed, MD) 
15. 
NCT03079
167 
Erythropoietin for Hypoxic-
Ischemic Encephalopathy in 
Newborns (PAEAN Trial) 
III 
1000 IU/kg rEpo i.v. <23 
h, and at 2, 3, 5, and 7 
days after birth, 
combined with 
therapeutic hypothermia 
Death or moderate to 
severe impairment; 
GMFA and BSID-III 
Index Scores at 24 
months of age 
University of 
Sydney, 
Australia (Helen 
Liley, MD) 
All ongoing single and multi-center trials investigating the effects of neurotherapies and 
therapeutic hypothermia in neonates with hypoxic-ischemic encephalopathy. Trials registered 
at ClinicalTrials.gov. HIE, hypoxic-ischemic encephalopathy; MRI, magnetic resonance 
imaging; BSID, Bayley Scale of Infant Development; GMFA, Generalized Motor Function 
Assessment; per os, per mouth; CO2, carbon dioxide; Lac/NAA ratio, lactate/N-acetyl-
aspartate ratio; MRS, magnetic resonance spectroscopy; IU, international units; rEpo, 
recombinant human erythropoietin; i.v., intravenous; HPDSC, human placental-derived stem 
cells; DTI, Diffusion Tensor Imaging. 
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Figure Legend 
Figure 1. Changes in fetal extradural temperature (top panel), cortical impedance (middle 
panel) and electroencephalogram (EEG) power (bottom panel), after 30 minutes of global 
cerebral ischemia in the near-term fetal sheep. Cortical impedance is a measure of cellular 
swelling in the parietal cortex. Fetuses received either sham-ischemia plus sham-cooling 
(clear), ischemia with sham cooling (black) or cerebral hypothermia started 3 hours after 
reperfusion, and continued until 48 hours (red), 72 hours (blue), or 120 hours (green). Cerebral 
ischemia starts at time zero. All hypothermia groups showed complete suppression of 
secondary rise in cortical impedance (i.e. it abolished delayed cell swelling), and substantially 
greater recovery of EEG power after resolution of late seizures. However, hypothermia for 48 
hours was associated with relapse of EEG power when cooling was discontinued, and reduced 
cortical impedance from 120 hours onwards (i.e. which is believed to represent cell loss). 
There was no significant difference between hypothermia for 3 days or 5 days in either EEG 
power or cortical impedance. Histological analyses showed loss of neuronal cells in the 
parasagittal cortex in the ischemia sham-cooling, and hypothermia for 2 and 5 days groups, 
compared to sham-ischemia sham-cooling. Neuronal survival in the cortex was greatest in the 
ischemia 3-day hypothermia group (see insert). Data are mean ± SEM. *P<0.05 vs. sham-
ischemia sham-cooling group, #P<0.05 vs. ischemia-sham cooling group. Data derived from 
Davidson et al [37, 38]. 
 
 
 
 
